Sepsis Pipeline 2016 Therapeutics Development Market Report

PUNE, India, August 17, 2016 /PRNewswire/ --

RnRMarketResearch.com adds "Sepsis - Pipeline Review, H1 2016" market research report with a comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sepsis and special features on late-stage and discontinued projects.

Complete report on H1 2016 pipeline review of Sepsis with 77 market data tables and 15 figures, spread across 240 pages is available at http://www.rnrmarketresearch.com/sepsis-pipeline-review-h2-2016-market-report.html .

Sepsis is an illness in which the body has a severe response to bacteria or other germs. Sepsis occurs when chemicals released into the bloodstream to fight the infection trigger inflammation throughout the body. This response may be called systemic inflammatory response syndrome (SIRS). Symptoms of sepsis include chills, shaking, difficulty breathing, decrease in platelet count, abnormal heart pumping function and abdominal pain. The predisposing factors include age and weakened immune systems. Treatment includes antibiotics and vasopressor.

Sepsis pipeline therapeutics constitutes close to 97 molecules. Out of which approximately 77 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 9, 4, 1, 53, 4 and 2 respectively. The report also reviews key players involved in the therapeutic development for Sepsis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies discussed in this Sepsis Pipeline Review, H1 2016 report include Adrenomed AG, Altor BioScience Corporation, Am-Pharma B.V., Arch Biopartners, Inc., Aridis Pharmaceuticals LLC, Asahi Kasei Pharma Corp., Astellas Pharma Inc., Batu Biologics, Inc., Biomedica Management Corporation, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cell2B S.A., Chiesi Farmaceutici SpA, Chiome Bioscience, Inc., Cilian AG, Cognosci, Inc., Cytheris SA, Endacea, Inc., Evec, Inc., Huons Co., Ltd., Immune Response BioPharma, Inc., Immunethep, SA, ImmunNovative Developments SL, InflaRx GmbH, Inotrem S.A., Integrated BioTherapeutics, Inc., Lead Discovery Center GmbH, Merck & Co., Inc., Navigen Pharmaceuticals, Inc., OncoImmune, Inc., Opsona Therapeutics Limited, Orion Oyj, ProThera Biologics, LLC., Ra Pharmaceuticals, Inc., Recce Pty Ltd, Ribomic Inc., Shionogi & Co., Ltd., Silence Therapeutics Plc, SK Biopharmaceuticals Co., Ltd., Stemedica Cell Technologies, Inc., Syntiron LLC, TaiRx, Inc., Takeda Pharmaceutical Company Limited, Therakind Limited, Therashock, LLC, TiGenix NV, VBS Pharmaceuticals ,ViiV Healthcare Limited and XImmune AB.

Order a copy of H1 2016 sepsis pipeline review market research report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=662424 .

Drug Profiles discussed in this research report are 3K3A-APC, 7-H9, AB-022, AcPepA, adrecizumab, ALT-836, AM/AMBP-1, Aspidasept, Atu-111, BI-113823, Biologic to Inhibit PD-L1 for Immunology, BMS-936559, BMS-986189, BRL-44408, BTZO-2, CAR Peptide, ceftaroline fosamil, COG-133, Cx-611, CYT-107, Drug for Sepsis and Septic Shock, Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders, Drugs to Inhibit Sialidase for Sepsis, Escherichia coli vaccine, ethinyl estradiol sulfonate, EV-007156, Gamma-PN, Glyco-23, HBN-1, HBN-3, HBN-4, HU-003, IFX-1, ImmStem, ImmuneSafe, IMT-504, IND-006, IR-999, Klebsiella pneumoniae vaccine, L-257, L-97-1, L-Citrulline, levosimendan, M-33, M-6229, meropenem, Metablok, Micselon, Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders, Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease, Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease, Monoclonal Antibody for Pancreatic Cancer, Sepsis and Disseminated Intravascular Coagulation, Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease, Monoclonal Antibody to Inhibit iNOS for Sepsis, Motrem, NAV-838, OPN-305, OTP-300, Peptide to Agonize GHSR-1a for Acute Ischemic Stroke, Acute Radiation Syndrome, and Sepsis, PNV-1, Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis, RA-101295, RBM-005, RECCE-327, Recombinant Alkaline Phosphatase Replacement for Sepsis, Recombinant Human Alkaline Phosphatase Replacement for Ulcerative Colitis, Acute Renal Failure, Sepsis and Hypophosphatasia, Recombinant Protein C for Sepsis, Stroke and Radiation Toxicity, Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis, Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation, Recombinant Protein for Inflammation and Bacterial Sepsis, Recombinant Protein for Sepsis, Recombinant Protein to Target Lipopolysaccharide for Sepsis, S-649266, SAN-101, Slit2N, Small Molecule for Immunology, CNS, Cardiovascular and Infectious Disease and more.

Explore more reports on Infectious Diseases Therapeutics.

About Us: 

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel:  +1-888-391-5441
sales@rnrmarketresearch.com

Connect with Us: 
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
Twitter: https://twitter.com/RnRMR
Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345
RSS / Feeds: http://www.rnrmarketresearch.com/feed

SOURCE RnR Market Research